Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
SynopsisP

Malaria update

Erica Weir
CMAJ February 15, 2005 172 (4) 473; DOI: https://doi.org/10.1503/cmaj.045270
Erica Weir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 Canadian Medical Association or its licensors

Background and epidemiology: In November 2004 the Public Health Agency of Canada released a travel health advisory warning of the risk of malaria in the Dominican Republic after receiving notice of 3 laboratory-confirmed cases of Plasmodium falciform malaria in Canadian travellers who had visited the country within the previous month. P. falciform is a mosquito-borne parasite that, through successive stages of its life cycle, invades the liver and then erythrocytes of infected humans. The infection can be fatal if it progresses to severe anemia or cerebral malaria (through the adhesion of infected erythrocytes to cerebral capillaries).

Figure1

Figure. Photo by: CDC/Jim Gathany

Malaria used to be endemic in Canada. During the building of the Rideau Canal in Ottawa in the 1820s, more than 500 workers and countless other settlers succumbed to infection from the temperate species P. vivax. Today, thanks to environmental and infection control interventions and changing local ecologies, the threat of malaria in Canada has been reduced to an international travel-related illness. This is not the case for much of the rest of the world, where malaria continues to threaten nearly 40% of the global population, accounting for 3–5 million deaths and 300–500 million new cases annually. In recent years global resources have been mobilized to fight malaria in the very poor countries of the world, mostly in Africa and Asia, through initiatives such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Malaria Vaccine Initiative.

Clinical management: The 3 recent cases of malaria in Canadian travellers returning from the Dominican Republic serve as a strong reminder for Canadian physicians to take a systematic, comprehensive approach to the investigation of fever in the international traveller, such as that outlined by the Committee to Advise on Tropical Medicine and Travel (www.phac-aspc.gc.ca/publicat/ccdr-rmtc/97vol23/23sup/acs1.html). The “gold standard” for diagnosis of malaria is the thick and thin peripheral blood smear, stained with Giemsa stain. The rapid malarial test provides a simple alternative, with overall sensitivity and specificity levels of about 90%, which fall dramatically with low-level parasitemia.1 Treatment of malaria may be oral or parenteral and depends on the infecting Plasmodium species, the geographic area of acquisition and the severity of infection.1

Prevention: Environmental measures to reduce mosquito breeding sites, personal protective measures to reduce the risk of mosquito bites and chemoprophylaxis appropriate for the geographic area of potential exposure remain the mainstays of prevention.1 Malaria vaccine development has seen a surge of activity in the last decade or so, owing largely to the mobilization of global funds and the advances made in the field of genetic engineering and biotechnology.2 The 3 immediate goals of vaccine research are the induction of strong, strain-transcending, durable immune responses; the identification of protective antigens for immunity at specific stages of the parasite's life cycle (pre-erythrocytic, erythrocytic and sexual); and the successful combination of candidate immunogens.3 Several candidate antigens that induce immune responses in the pre-erythrocytic stage (e.g., circumsporozoite protein and the thrombospodin-related adhesive protein) and the erythrocytic stage (e.g., merozoite surface protein) have been identified, and vaccine trials involving humans and primates are underway. However, beyond the identification of immunogenic antigens, further considerations challenge vaccine development. They pertain to technical issues, such as determining the form and delivery of the vaccine (e.g., synthetic peptide, recombinant, DNA plasmid) and understanding and effecting T-cell protection, and to logistical issues such as combining vaccine development efforts, licensing vaccines for use in very young children, acquiring informed consent in communities with low levels of literacy, and predicting and controlling costs.

Optimists in the field of malaria vaccine development suggest that, with sustained funding and dedicated cooperation, an available effective vaccine formulation is about 10 years away.3

References

  1. 1.↵
    Suh KN, Kain KC, Keystone JS. Malaria. CMAJ 2004;170(11):1693-702.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Chauhan VS, Bhardwaj D. Current status of malaria vaccine development. Adv Biochem Eng Biotechnol 2003;84:143-83.
    OpenUrlPubMed
  3. 3.↵
    Moorthy VS, Good MF, Hill AV. Malaria vaccine developments [review]. Lancet 2004;363:150-6.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (4)
CMAJ
Vol. 172, Issue 4
15 Feb 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Malaria update
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Malaria update
Erica Weir
CMAJ Feb 2005, 172 (4) 473; DOI: 10.1503/cmaj.045270

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Malaria update
Erica Weir
CMAJ Feb 2005, 172 (4) 473; DOI: 10.1503/cmaj.045270
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Scopus (2)
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Travel medicine
    • Drugs: immunologic

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Copyright and Permissions
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2019, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire